Frankfurt
08.10.26 | 08:02
0,117 Euro
+2,10 % +0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,121 | 0,134 | 21:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:54 | Mauna Kea Technologies Announces 2026 Half-Year Results | 276 | Business Wire | Product and service revenue of €3.2 million, up 37% driven by strong CellTolerance momentum in Europe and new international markets Gross margin on product and service revenue of 65%, up 2 points... ► Artikel lesen | |
| Di | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 351 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 07.09. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 430 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 26.08. | Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer | 538 | Business Wire | Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients Original research conducted and funded by Korea's National Evidence-Based Healthcare... ► Artikel lesen | |
| 07.08. | Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital | 566 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 28.07. | Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio and Its Combination with AI for the Diagnosis of Pancreatic Cysts | 537 | Business Wire | International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio AI Cellvizio increases accuracy... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth | 504 | Business Wire | H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1 CellTolerance sales increased +145% to €0.9 million, driven by strong international expansion Strong... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity | 443 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies Secures €4 Million Optional Shareholder Loan To Support Commercial Expansion | 2 | pulse2.com | ||
| 15.07. | Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth | 735 | Business Wire | Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing... ► Artikel lesen | |
| 06.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 358 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.06. | Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026 | 500 | Business Wire | All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio,... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 445 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio- Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis | 382 | Business Wire | 100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance Commercial Installation | 492 | Business Wire | IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27% An ideal region uniquely positioned for CellTolerance's direct out-of-pocket commercial... ► Artikel lesen | |
| 18.05. | Mauna Kea Technologies Announces Nomination of 3 New Directors | 646 | Business Wire | Their recognized expertise will help accelerate the strategic transformation launched in 2025 Subject to approval at upcoming Annual General Meeting
Regulatory News:
Mauna Kea Technologies... ► Artikel lesen | |
| 04.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 402 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2025 Annual Financial Report | 1.041 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio To Be Presented at Digestive Disease Week 2026 | 820 | Business Wire | 10 Cellvizio-related abstracts, including landmark multicenter pancreatic cyst data, AI-driven IBD assessment, and new food intolerance applications, reinforce the breadth and depth of real-time... ► Artikel lesen | |
| 22.04. | Mauna Kea Technologies meldet starkes Wachstum im ersten Quartal 2026 | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,073 | -1,88 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| FAMICORD | 2,970 | -1,33 % | EQS-News: FamiCord AG gewinnt vielversprechenden CDMO-Neukunden mit Herstellungsvereinbarung für zulassungsrelevante Phase-II/III-Studie bei anfänglichem Volumen im niedrigen einstelligen Millionen-Euro-Bereich | EQS-News: FamiCord AG
/ Schlagwort(e): Vertrag
FamiCord AG gewinnt vielversprechenden CDMO-Neukunden mit Herstellungsvereinbarung für zulassungsrelevante Phase-II/III-Studie bei... ► Artikel lesen | |
| GERATHERM MEDICAL | 1,975 | -1,74 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| CERENOME | 1,362 | +3,65 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| MEDICLIN | 5,050 | -1,94 % | Mediclin: Indirekter Profiteur | Sondersituationen wie Übernahmen, Turnarounds oder Abfindungsspekulationen sind gerade in der Spezialwerteszene eine beliebte Anlagestrategie. So rückte im Herbst 2025 etwa der auf den Reha-Bereich... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,220 | +0,91 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| VERU | 2,405 | -2,24 % | Veru Inc.: Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial | ||
| LIFEWARD | 6,400 | -0,16 % | Lifeward Ltd. - 8-K, Current Report | ||
| LIGHT AI | 0,020 | 0,00 % | Light AI Inc: Light to continue to develop QuickScan strep A system | ||
| IMUNON | 1,080 | 0,00 % | Neues Krypto-Bänkli in Vaduz zittert: Bekannter Ex-Bär-Boss Paul Arni will mit Celsion durchstarten ... | ||
| FRESENIUS | 41,590 | -3,92 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius erwirbt verbleibende 45 % an mAbxience für bis zu 750 Mio. € und erhält vollständige Kontrolle über seine Biosimilars-Plattform | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Strategische Unternehmensentscheidung
Fresenius erwirbt verbleibende 45 % an mAbxience für bis zu 750 Mio. € und erhält vollständige... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 36,720 | -1,87 % | EQS-Adhoc: Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen Giza | EQS-Ad-hoc: Fresenius Medical Care AG / Schlagwort(e): Personalentscheidungen / Vorstand
Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,260 | -0,78 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +2,10 % bei einem Aktienkurs von 0,117 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.